PENGUINBIO offers the first molecular test enabling early detection of gut barrier disruption and preventing diseases before they arise.
Developed for astronauts, designed to protect human health on Earth.
What if we could prevent disease before it begins?
This question has shaped the thinking of our founder, Dr. Peter Rappl, for many years.
As an experienced scientist with a PhD in molecular life sciences and a background spanning academic research, diagnostics, and translational innovation, Peter recognised a fundamental gap in modern medicine. While many chronic and systemic diseases are treated only after symptoms appear, the earliest biological signals often go undetected.
Driven by this insight, he set out to tackle one of the most underestimated factors of human health: the integrity of the gut barrier.
PENGUINBIO was founded to make gut barrier dysfunction measurable.
We are developing the first molecular diagnostic test designed to enable early detection of intestinal permeability, long before irreversible disease processes unfold.
Originally developed with the extreme demands of spaceflight medicine in mind within ESA BIC and Space2Health, our technology addresses the needs of one of the most vulnerable populations: astronauts. At the same time, it holds the potential to protect a billion people on Earth through earlier intervention and preventive care.
At PENGUINBIO, we believe that prevention starts with measurement. On Earth and beyond.
our technology
We identified a key modulator of intestinal tight junctions. Our proprietary antibody binds with high specificy, detecting early barrier disruption before inflammation occurs.
Using small serum volumes, our test provides quantitative readouts that reveal subtle changes in gut permeability.
Validated in astronauts and clinical cohorts, our platform enables precision prevention. Bridging space medicine and global health.
partners & programes
PENGUINBIO is proudly supported by the European Space Agency Business Incubation Centre (ESA BIC Hessen & BaWü), push! Stipendium Hessen, and is a member of the Space2Health initiative.
With additional partners and academic collaborators, we accelerate our journey.
behind PENGUINBIO
-
peter rappl
founder, ceo & scientific lead
-
desiree schröder
shareholder
Contact us via hello@penguinbio.com , if you are:
A biobank with access to astronaut samples or other applicable cohorts to support our validation
An assay developer in the IVDR landscape
An investor willing to accelerate our market entry
or you know someone of the above or consider yourself a sparring partner with similar scientific discoveries related to gut health
If you are you none of the above but still want to support us, donate today, follow us
and help amplify our idea through visibility.